Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators.

JAMA. 2004 Nov 10;292(18):2227-36.

PMID:
15536109
2.
3.

Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.

Wong GW, Laugerotte A, Wright JM.

Cochrane Database Syst Rev. 2015 Aug 26;(8):CD007449. doi: 10.1002/14651858.CD007449.pub2. Review.

PMID:
26306578
4.

Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.

Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C.

Am J Cardiovasc Drugs. 2006;6(4):209-17. Review.

PMID:
16913822
5.

Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.

Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C.

Vasc Health Risk Manag. 2007;3(1):31-7. Review.

PMID:
17583173
6.

Use of carvedilol in hypertension: an update.

Leonetti G, Egan CG.

Vasc Health Risk Manag. 2012;8:307-22. doi: 10.2147/VHRM.S31578. Epub 2012 May 18. Review.

PMID:
22661898
7.

β-blockers: a review of their pharmacological and physiological diversity in hypertension.

Ripley TL, Saseen JJ.

Ann Pharmacother. 2014 Jun;48(6):723-33. doi: 10.1177/1060028013519591. Epub 2014 Mar 31. Review.

PMID:
24687542
8.

Carvedilol in hypertension treatment.

Stafylas PC, Sarafidis PA.

Vasc Health Risk Manag. 2008;4(1):23-30. Review.

PMID:
18629377
9.

Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.

Talbert RL.

Heart Fail Rev. 2004 Apr;9(2):131-7. Review.

PMID:
15516861
11.

Pharmacological interventions for hypertension in children.

Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R.

Cochrane Database Syst Rev. 2014 Feb 1;(2):CD008117. doi: 10.1002/14651858.CD008117.pub2. Review.

PMID:
24488616
12.

Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.

Bauman JL, Talbert RL.

J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):117-28. Review.

PMID:
15309248
13.

Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.

Frishman WH, Henderson LS, Lukas MA.

Vasc Health Risk Manag. 2008;4(6):1387-400. Review.

PMID:
19337551
14.

Beta-blockers and diabetes: the bad guys come good.

Cruickshank JM.

Cardiovasc Drugs Ther. 2002 Sep;16(5):457-70. Review.

PMID:
12652116
15.

[Metoprolol in the treatment of essential hypertension].

Minushkina LO, Sidorenko BA.

Kardiologiia. 2003;43(11):102-5. Review. Russian.

PMID:
14671567
16.

Diabetes and hypertension. What is new?

Barrios V, Escobar C.

Minerva Cardioangiol. 2009 Dec;57(6):705-22. Review.

PMID:
19942843
17.

Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

McGill JB.

Vasc Health Risk Manag. 2010 Jun 1;6:363-72. Review.

PMID:
20539838
18.

[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].

Charpentier G, Puel J, Steg PG.

Presse Med. 2005 Oct 22;34(18):1295-8. Review. French.

PMID:
16269992
19.

Recent developments in the treatment of type 2 diabetes mellitus.

Ruilope LM.

Cardiovasc Drugs Ther. 2003 Mar;17(2):151-8. Review.

PMID:
12975597
20.

Is it time to replace propranolol with carvedilol for portal hypertension?

Abid S, Ali S, Baig MA, Waheed AA.

World J Gastrointest Endosc. 2015 May 16;7(5):532-9. doi: 10.4253/wjge.v7.i5.532. Review.

PMID:
25992192

Supplemental Content

Support Center